PT - JOURNAL ARTICLE AU - Qian, Fang AU - Gao, Guiju AU - Song, Yangzi AU - Xu, Yanli AU - Wang, Aibin AU - Wang, Sa AU - Hao, Yiwei AU - Chen, Meiling AU - Ma, Xiaoyang AU - Zhao, Tianwei AU - Guo, Xiaodi AU - Chen, Zhihai AU - Zhang, Fujie TI - Specific Dynamic Variations in the Peripheral Blood Lymphocyte Subsets in COVID-19 and Severe Influenza A Patients: A Retrospective Observational Study AID - 10.1101/2020.08.15.20175455 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.15.20175455 4099 - http://medrxiv.org/content/early/2020/08/17/2020.08.15.20175455.short 4100 - http://medrxiv.org/content/early/2020/08/17/2020.08.15.20175455.full AB - Background Both COVID-19 and influenza A contribute to increased mortality among the elderly and those with existing comorbidities. Changes in the underlying immune mechanisms determine patient prognosis. This study aimed to analyze the role of lymphocyte subsets in the immunopathogenesisof COVID-19 and severe influenza A, and examined the clinical significance of their alterations in the prognosis and recovery duration.Methods By retrospectively reviewing of patients in four groups (healthy controls, severe influenza A, non-severe COVID-19 and severe COVID-19) who were admitted to Ditan hospital between 2018 to 2020, we performed flow cytometric analysis and compared the absolute counts of leukocytes, lymphocytes, and lymphocyte subsets of the patients at different time points (weeks 1- 4).Results We reviewed the patients’ data of 110 healthy blood donors, 80 Non-severe-COVID-19, 19 Severe-COVID-19 and 43 severe influenza A. We found total lymphocytes (0.93 ×109/L, 0.84 ×109/L vs 1.78 ×109/L, P < 0.0001) and lymphocyte subsets (T cells, CD4+ and CD8+ T cell subsets) of both severe patients to be significantly lower than those of healthy donors at early infection stages. Further, significant dynamic variations were observed at different time points (weeks 1–4).Conclusions Our study indicates lymphopenia to be associated with disease severity and suggests the plausible role of lymphocyte subsets in disease progression, which in turn affects prognosis and recovery duration in patients with severe COVID-19 and influenza A.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Ethics Committee of Beijing Ditan HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.COVID-19Coronavirus disease-19WHOWorld Health OrganizationSARS-CoV-2Severe acute respiratory syndrome coronavirus 2CTComputed tomographyRT-PCRReverse transcription-polymerase chain reactionRNARibonucleic acidHIVhuman immunodeficiency virusCOPDchronic obstructive pulmonary diseaseCDCCenter for Disease Control and PreventionNKnatural killerIQRinterquartile rangeHChealthy controlsWBCWhite blood cellsLYLymphocytesACE-2angiotensin-convertingenzyme 2MERS- CoVMiddle East Respiratory Syndrome coronavirusSARS-CoVSevere acute respiratory syndrome coronavirus